ArticleTranslational oncology2022

High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma.

Laura Kohtamäki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.